CMS Invites Clinicians to Participate in Study on Burdens of MIPS Reporting

Feb. 26, 2018
CMS plans to study the hardships associated with reporting quality measures under the Merit-Based Incentive Payment System (MIPS) and is inviting clinicians to apply to participate in the research.

The Centers for Medicare & Medicaid Services (CMS) plans to study the hardships associated with reporting quality measures under the Merit-Based Incentive Payment System (MIPS) and is inviting clinicians to apply to participate in the research.

CMS is specifically looking to study clinical workflows and data collection methods using different submission systems to examine the burdens associated with reporting quality measures in 2018, as outlined in the Quality Payment Program Year 2, under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The agency also wants to understand the challenges that clinicians have in the collection and reporting of quality data with the aim of recommending changes to try to lower clinicians’ burden, improve quality data collection and reporting, and enhance clinical care.

According to CMS, MIPS-eligible clinicians participating in MIPS as an individual or as part of a group and that participate successfully in the study will earn full credit for the 2018 MIPS Improvement Activities performance category. CMS also will include a limited number of clinicians who aren’t eligible for MIPS in 2018 for the study.

CMS is accepting applications for the study through March 23, 2018. Clinicians will be notified by email in spring 2018 if they are selected for the study. An application to participate in the study can be found here.

The study will run from April 2018 to March 2019. To successfully compete the study and earn full Improvement Activity credit, clinicians who are chosen to participate will have to complete a 2017 MIPS participation survey in April/May 2018 and a 2018 MIPS planning survey in September/October 2018. Participating clinicians, if invited by the study team, may also have to join a virtual 90-minute focus group between November 2018 and February 2019. And, clinicians will have to meet the minimum requirements for the MIPS Quality performance category by submitting data for at least three measures in the MIPS Quality performance category, as required for 2018 MIPS participation. The data submitted must include one outcome measure, be submitted to CMS by the March 31, 2019 final MIPS reporting deadline and be submitted through any method accepted under MIPS for Year 2 of the QPP.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1